GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO 주식 보고서

시가총액: ₹451.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GlaxoSmithKline Pharmaceuticals 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bhushan Akshikar

최고 경영자

₹66.9m

총 보상

CEO 급여 비율21.7%
CEO 임기1.8yrs
CEO 소유권n/a
경영진 평균 재임 기간2yrs
이사회 평균 재임 기간6.5yrs

최근 관리 업데이트

Recent updates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Jun 01
Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

May 05
With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Jul 07
Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

CEO 보상 분석

Bhushan Akshikar 의 보수는 GlaxoSmithKline Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

₹6b

Mar 31 2024₹67m₹15m

₹6b

Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹6b

Jun 30 2023n/an/a

₹6b

Mar 31 2023₹34m₹4m

₹6b

보상 대 시장: Bhushan 의 총 보상 ($USD 801.95K )은 Indian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 631.48K ).

보상과 수익: Bhushan 의 보상은 지난 1년 동안 20% 이상 증가했습니다.


CEO

Bhushan Akshikar

1.8yrs

테뉴어

₹66,885,000

보상

Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...


리더십 팀

이름위치테뉴어보상소유권
Bhushan Akshikar
MD & Executive Director1.8yrs₹66.89m데이터 없음
Juby Chandy
Whole-Time Director & CFO2.5yrs₹68.92m데이터 없음
Chinmay Sharma
Executive Vice President of Human Resources3.8yrs₹37.40m데이터 없음
Aparajita Rajput
Vice President of Technologyless than a year데이터 없음데이터 없음
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretaryno data₹11.57m데이터 없음
Amit Pandey
Executive Vice President of Legal2.7yrs데이터 없음데이터 없음
Simrat Sohal
Vice President of Ethics & Compliance1.7yrs데이터 없음데이터 없음
Ransom D'Souza
Executive Vice President of Communications & Government Affairs7.5yrs데이터 없음데이터 없음
Sukanya Choudhary
Executive Vice-President of Regulatory Affairsno data데이터 없음데이터 없음
Shourov Mukherjee
Executive Vice-President of Adult Vaccines2.3yrs데이터 없음데이터 없음
Upendra Singh
Executive Vice President of General Medicines1.8yrs데이터 없음데이터 없음
Sharmishta Mitra
Commercial Head - Paediatric Vaccines1.8yrs데이터 없음데이터 없음

2.0yrs

평균 재임 기간

경험이 풍부한 관리: GLAXO 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Bhushan Akshikar
MD & Executive Directorno data₹66.89m데이터 없음
Juby Chandy
Whole-Time Director & CFO2.5yrs₹68.92m데이터 없음
Renu Karnad
Non-Executive Chairperson5.5yrs₹3.25m데이터 없음
Manu Anand
Independent Director2.4yrs₹2.65m데이터 없음
Damodarannair Sundaram
Non-Executive Independent Director15.3yrs₹2.70m데이터 없음
Subesh Williams
Non Executive Director7.5yrs데이터 없음데이터 없음
Pradeep Bhide
Non-Executive Independent Director14yrs₹2.70m데이터 없음
Anami Narayan Roy
Non-Executive Independent Director12.9yrs₹2.45m데이터 없음
Sunita Maheshwari
Non-Executive & Independent Director4.4yrs₹2.45m데이터 없음

6.5yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: GLAXO 의 이사회경험(평균 재직 기간 6.2 년)으로 간주됩니다.